QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY.
J Nucl Med. 2021 Jan 8:jnumed.120.256602. doi: 10.2967/jnumed.120.256602. Online ahead of print.
J Nucl Med. 2021.
PMID: 33419944